Physician profile
James B Martel
NPI 1851312300
$3,713.48
in general payments reported to CMS, 2019-2025
26 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $171 · 2021: $391 · 2022: $430 · 2023: $714 · 2024: $818 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,561.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $730.23 | 2022-2025 | Rocklatan, Tryptyr, Centurion |
| Abbvie INC. | $569.43 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $378.44 | 2024-2025 | Vyzulta, Miebo |
| Biotissue Holdings INC. | $252.41 | 2020-2024 | |
| Oyster Point Pharma, INC. | $217.42 | 2022-2025 | Tyrvaya |
| Amgen INC. | $159.59 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $158.07 | 2023-2025 | Syfovre |
| Allergan, INC. | $155.07 | 2019-2022 | |
| Horizon Therapeutics Plc | $154.14 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.59 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $129.27 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $101.72 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $67.11 | 2020-2023 | Acthar |
| Harrow Eye, LLC | $65.05 | 2025 | Vevye, Iheezo |
| Aerie Pharmaceuticals, INC. | $63.53 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $61.87 | 2022 | |
| Astellas Pharma US INC | $59.16 | 2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $58.12 | 2019-2022 | |
| Optos, INC. | $39.28 | 2019 | |
| Kala Pharmaceuticals, INC. | $32.97 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $29.96 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Mallinckrodt Enterprises LLC | $23.17 | 2019 | |
| Sight Sciences, INC. | $19.57 | 2023 | Tearcare System |
| Dompe US, INC. | $19.12 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $18.51 | 2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $15.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Martel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.